Reinvigorating a natural pathway to relieve intraocular pressure
This article was originally published in Start Up
The gold standard for treating refractory glaucoma, trabeculectomy creates an artificial pathway to relieve intraocular pressure by forming an external bleb or blister under the eyelid so that aqueous humor fluid can drain from inside the eye to the bleb. Solx Inc. has developed an implantable device that improves on that method. The Solx Gold Shunt is a flat tube that detours fluid within the eye by using an existing pathway (the suprachoroidal space) that gradually shuts down as one ages. The shunt reconnects and reinvigorates this outflow pathway.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.